Olmesartan Glenmark Pharmaceuticals Europe (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Glenmark Pharmaceuticals Europe, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartan Glenmark Pharmaceuticals Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Glenmark Pharmaceuticals Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps lower systolic and diastolic blood pressure in adults. - Heart failure: used as part of combination therapy to improve cardiac output and reduce hospitalisation risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.

Olmesartan medoxil may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing Olmesartan medoxil, clinicians should consider several safety aspects.

- Renal function monitoring: assess baseline creatinine and eGFR, especially in patients with chronic kidney disease. - Electrolyte balance: check serum potassium periodically, as hyperkalaemia may occur. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity. - Concomitant NSAID therapy: may reduce antihy‑pertensive effect and increase renal risk. - Elderly patients: start with a lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in the original packaging , protect from moisture.

Olmesartan medoxil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., lisinopril, aliskiren) – heightened risk of hypotension, hyperkalaemia and renal impairment. - Potassium‑rich supplements or potassium‑sparing diuretics – may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflamatory    --- - NSAIDs: may blunt antihypertensive response and affect renal function. - Diuretics (thiazide or loop): may enhance hypotensive effect; monitor blood pressure. - Lithium: increased lithium levels and risk of toxicity. - CYP  ---        ---